Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
